Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
BALTIMORE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology. The data, published on medRxiv, demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity. With clinical evidence that the c-srRNA platform is safe and can produce a T cell-mediated response, the Company is exploring its potential for the development of vaccines, cell therapies and immunotherapies for several indications.
- The data, published on medRxiv , demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity.
- The results from this trial suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
- This allows for the vaccine to be delivered intradermally, which is a method that’s been shown to induce strong T cell-mediated immunity.
- Data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.